PharmaGossipAtLast

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Tuesday, June 18, 2013

Young Law Group Announces Initiative Prosecuting Alleged Pharmaceutical Industry Kickbacks

Posted on 7:10 PM by Unknown


Philadelphia, PA (PRWEB) June 18, 2013

Young Law Group, a leader in whistleblower law and False Claims Act litigation, announces a False Claims Act initiative aimed at ferreting out alleged, unlawful kickbacks in the healthcare industry.

This YLG initiative builds on back-to-back kickback complaints by U.S. Attorney Preet Bharara in the Southern District of New York in late April alleging that Swiss pharmaceutical manufacturer Novartis (ADR) engaged in multimillion dollar kickbacks to physicians from 2002 through 2011 inducing doctors to prescribe Novartis drugs that were paid for by Medicare and Medicaid, joining a False Claims Act qui tam lawsuit initially filed by Young Law Group, and a related complaint alleging kickbacks to twenty or more pharmacies in exchange for their switching transplant patients from competitor drugs to NOVARTIS’s drug, Myfortic.

Among other illegal actions, U.S. Attorney Preet Bharara’s complaint alleging Novartis kickbacks to physicians details abusive speaker programs and payments. “As alleged, Novartis corrupted the prescription drug dispensing process with multi-million dollar ‘incentive programs’ that targeted doctors who, in exchange for illegal kickbacks, steered patients toward its drugs,” U.S. Attorney Preet Bharara said issuing the complaint.

Bharara’s prosecution of alleged pharmaceutical industry kickbacks is part and parcel of broader U.S. Attorney for the Southern District of New York enforcement initiatives according to an April 8, New York Law Journal analysis.

“Conscientious U.S. Attorneys are now employing anti-kickback litigation to pursue False Claims Act prosecutions, costing taxpayers hundreds of millions if not billions of dollars, in this sea change in enforcement,” Eric L. Young said.

Young Law Group’s false claims (qui tam) initiative addresses this sea change in enforcement.

Kickback allegations are not uncommon in the pharmaceutical industry. For instance, on May 27, The Financial Post reported thatIsta Pharmaceuticals Inc., a unit of Bausch & Lomb Inc. agreed to pay $33.5 million to resolve federal claims of misbranding and paying kickbacks related to the drug Xibrom. In March, two formerWarner Chilcott PLC employees brought a false claims suit that the pharmaceutical manufacturer offered physicians kickbacks to generate prescriptions thereby overbilling Medicare and Medicaid.

Kickbacks violate International Federation of Pharmaceutical Manufacturers & Associations standards and practices. For instance, regarding wining and dining physicians to induce them to prescribe certain drugs, the international association of pharmaceutical manufacturer association rules that “refreshments and/or meals incidental to the main purpose of the event can only be provided: exclusively to participants of the event; and if they are moderate and reasonable as judged by local standards.

“In a climate where enforcement matters more and more, we are delighted to respond to pharmaceutical industry professionals, physicians, hospitals and Medicare and Medicaid professionals, concerned about false or fraudulent billings,” Young said.

U.S. Attorney Preet Bharara’s complaint regarding physicians (justice.gov/usao/nys/pressreleases/April13/Novartis2LawsuitPR/US%20v.%20Novartis%20Relator%202nd%20Amended%20Complaint%2011civ00071%20.pdf) is Case Number 11 Civ.0071 and his complaint regarding pharmacies (justice.gov/usao/nys/pressreleases/April13/NovartisLawsuitPR/Novartis%20Pharmaceuticals%20Corporation%20-%20Complaint%20in%20Intervention%20%2811%20Civ%208196%29.pdf) is Case Number 11 Civ. 8196.

Young Law Group specializes in representing whistleblowers ("relators") throughout the United States and internationally in qui tam lawsuits brought under the False Claims Act. The False Claims Act allows private individuals to sue companies that are defrauding the federal government and to recover funds on the government's behalf. Whistleblowers may be entitled to 15 percent to 30 percent of civil recoveries resulting from a qui tam lawsuit.

Contact: Young Law Group by email by clicking on Mr. Young's name on the right or visit us at http://www.young-lawgroup.com


Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Beautiful Barcelona! - Gedeon Richter ruled in breach of ABPI code
    LYNNE TAYLOR Gedeon Richter (UK) has breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, and has brough...
  • GlaxoChinaGate contd. - Bwaaa!
    China Drug Probe 'Unfair,' Euro Group Says Thu, 09/05/2013 - 8:30am Foreign companies believe they are unfairly being singled out fo...
  • Another day, another J&J recall ... Mold found in schizophrenia drug forces Johnson & Johnson recall
    By  Bloomberg News  on September 11, 2013 at 5:25 PM, updated  September 11, 2013 at 5:27 PM Johnson & Johnson has recalled 5,000 vials ...
  • AllTrials Update
    Dear Friends Support for AllTrials around the world is growing and we need to keep it that way as we reach some crucial debates. The Europea...
  • Hurrah!
    Press Release 11 September 2013 FOR IMMEDIATE RELEASE The HRA is now implementing its plans for ensuri...
  • Advertisement
    The book addresses, in great, evidence-based detail, a general system failure caused by widespread crime, corruption, bribery and impotent d...
  • Of pigs and penicillin
    Extended Withdrawal Needed to Avoid Penicillin G Residues News US - A minimum 51-day withdrawal is necessary if penicillin G is used in pigs...
  • The Lancet has formally retracted the Jikei Heart Study paper, originally published in 2007
    . The retraction had been widely anticipated for more than a month, after a series of news reports in Japan made it clear that the long-simm...
  • Wrigley holds off on caffeinated gum as FDA reviews caffeine
    By Melissa Healy 7:54 p.m. EDT, May 9, 2013 Less than a week after the Food and Drug Administration announced that it would investigate the ...
  • Petition by Professor David Healy - please sign if you agree
    Let us see Drug Data! Drug hazards are not “trade secrets”! Drug companies maximize the sales of new drugs by hyping their benefits while do...

Categories

  • Abbott (1)
  • alltrials (1)
  • alosetron (1)
  • AstraZeneca (1)
  • Baxter (1)
  • big pharma (2)
  • bribery (7)
  • Champix (1)
  • chantix (1)
  • china (7)
  • Clinical Trails (1)
  • Clinical Trial (1)
  • corruption (5)
  • Dan Markingson (1)
  • Dan Markingson Death (1)
  • diabetes (2)
  • Diovan (1)
  • EFPIA (1)
  • glaxo (11)
  • Glaxo China bribery corruption (1)
  • gsk (7)
  • hongbao (1)
  • insurance (1)
  • Januvia (1)
  • johnson and johnson (1)
  • Lotronex (1)
  • Mefloquine (1)
  • Mental Health (1)
  • Merck (2)
  • Novartis (1)
  • pancreas (1)
  • pfizer (1)
  • pharma (1)
  • pharmaceuticals (1)
  • PhRMA (1)
  • quetiapine (1)
  • Sanofi (2)
  • scandal (1)
  • seroquel (1)
  • side effects (1)
  • suvorexant (1)
  • ucb (1)
  • Valsartan (1)
  • Zaltrap (1)

Blog Archive

  • ▼  2013 (300)
    • ►  September (40)
    • ►  August (70)
    • ►  July (104)
    • ▼  June (81)
      • China detains GlaxoSmithKline staff for fraud: rep...
      • Get in the sack
      • Tamiflu saga continues - NYT. By Katie Thomas
      • Gouging the patient - 1boringoldman explains
      • Deen dumped
      • FDA shuts down 1,677 online pharmacies
      • Treasure Ireland contd.
      • SEC charges medical imaging firm CEO for lying on ...
      • Sleepy Seroquel
      • Federal lawmakers urge FDA to change rules to allo...
      • #UMNProud
      • Nemeroff in London - let's see the slides
      • Pfizer still on the asbestos hook
      • Meet the new Mr NICE Guy
      • Of the 86 drugs in the industry's diabetes pipelin...
      • Sometimes it is best to do nothing. A "must read "...
      • Evidence Based Medicine - Why we can’t trust clini...
      • Pharmaceutical scandal: 'You pay us £300. However,...
      • SCANDAL
      • Who's who at Quantum Pharmaceuticals?
      • Busted! No Solace for Quantum
      • Saying no to chemotherapy by Des Spence - BMJ
      • For you - special price!
      • Zalcrap contd.
      • Your puny western ads don't work on our Russian wo...
      • UK plans to cut some drug prices by up to 20 per cent
      • A Fistful of Dollars - The Cephalon off label way
      • A Smoking Pillbox: Evidence that Sgt. Bales May Ha...
      • Nine pharmas fined by EU
      • Jagemeister PR - you're doing it wrong
      • For AZ's Onglyza SAVOUR is not a saviour
      • EU fines Lundbeck for paying off pharma rivals
      • Young Law Group Announces Initiative Prosecuting A...
      • FDA Probes Deaths Linked to Long-Acting Zyprexa
      • A holy mess
      • J&J buy Aragon
      • Introducing polypill.com - medication for the mass...
      • FT - Professor turns to internet to distribute pol...
      • Shire Pharmaceuticals Ltd and Roche Products Limit...
      • NIH Censoring Expert to Prevent Criticism of Ethic...
      • Merck announces it will slash jobs at research lab...
      • AllTrials - the countdown begins
      • Experts Propose Restoring Invisible And Abandoned ...
      • The Painful Politics of Painkillers Opioids are de...
      • GSK - Little Trouble in Big China
      • No dishonour in depression
      • Healing the Overwhelmed Physician - by Jerry Avorn
      • GlaxoSmithKline Fires China R&D Boss for 'Misrepre...
      • Charles Nemeroff - Honoured in Britain, the US psy...
      • How Big Pharma Drives Up Medicare Spending Without...
      • Walgreens pays record $80 million settlement for i...
      • Has pancreatic damage from glucagon suppressing di...
      • Austerity is bull!
      • Obama administration reverses course on Plan B pill
      • Corporate Whistle Blower Center Now Urges Pharmace...
      • Endo Implodes
      • Introducing OTC Toolbox
      • Pearl bought
      • Johnson & Johnson seeks home court advantage in Ty...
      • The geography of antidepressant, antipsychotic, an...
      • One to watch - Dispatches, Channel 4, Monday June ...
      • How much is your doctor making from Big Pharma?
      • Not just Bad - Ineffective Pharma!
      • Not just Bad - Filthy Pharma
      • Big data to sniff out drug marketing fraud
      • Dr Sidney Wolfe retires with a bang!
      • Kerching!
      • No-user, no cry
      • Nine pharma firms face EU fines over pay-for-delay...
      • Here for a good time or a long time?
      • Yet another J&J recall!
      • The Myth of the New
      • Keepy-uppy!
      • Meet the Doctor Big Pharma Can't Shut Up
      • In Memoriam: Barbara A. Brenner, 1951-2013
      • Pink Ribbons Inc. - watch the movie
      • Gouging 101 spotted by Dr Judy Stone
      • Summer Reading contd. Blood Medicine by Kathleen S...
      • Corporate fines are puny
      • "Brad Abbey" on Ben Goldacre
      • AllTrials contd. - D Day for comments - June 10th
    • ►  May (5)
Powered by Blogger.